International Variability in Clinical Approaches to Clostridioides difficile Infections

Overview

A global survey of 359 healthcare professionals from 31 countries revealed substantial variability in the diagnosis, treatment, and secondary prophylaxis of Clostridioides difficile infections (CDI). Notably, differences were observed in diagnostic algorithms, first-line treatment choices, and use of secondary prophylaxis, highlighting a lack of international consensus.

Background

Clostridioides difficile infection is a major cause of healthcare-associated infections worldwide, with an estimated 8 million cases annually and significant morbidity, mortality, and economic burden. Multiple international guidelines exist but offer conflicting recommendations on CDI management, including diagnosis, treatment of initial and recurrent episodes, and prophylaxis. This inconsistency may contribute to heterogeneous clinical practices globally. Understanding these variations is critical to identifying knowledge gaps and guiding future clinical trials.

Data Highlights

Key Findings

• 75.8% of respondents use a 2-step diagnostic algorithm for CDI, but assay types vary widely.
• Significant variability exists in first-line treatments for initial and recurrent uncomplicated CDI episodes.
• No consensus was found on management strategies for fulminant CDI across regions.
• Secondary CDI prophylaxis during antibiotic re-exposure is most common in North America (84.1%), less so in other continents (50.0%) and Europe (31.0%).
• Oral vancomycin is the predominant agent for secondary prophylaxis (96.3%), but dosing (125–500 mg daily) and duration (1–28 days) vary significantly.
• These practice variations likely stem from divergent international guidelines and limited robust evidence.

Clinical Implications

Clinicians should recognize the considerable international heterogeneity in CDI management, particularly regarding diagnostic approaches and secondary prophylaxis. The variability underscores the need for standardized, evidence-based guidelines to optimize patient outcomes. Until more definitive data are available, individualized clinical judgment remains essential when managing CDI, especially in fulminant cases and during antibiotic re-exposure.

Conclusion

This survey highlights significant global variability in CDI diagnosis, treatment, and prophylaxis practices, reflecting divergent guidelines and evidence gaps. These findings emphasize the urgent need for randomized controlled trials to establish harmonized international best practices for CDI management.

References

1. McGill University Health Centre Research Ethics Board 2025 -- Survey on CDI Management
2. American College of Gastroenterology (ACG) Guidelines
3. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines
4. Infectious Diseases Society of America (IDSA) Guidelines